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Abstract: This study described the performance of carbon nanofiber modified chitosan (CNF@CS) composite microspheres for the
controlled release of the Ibrutinib (IBR) drug. The surface morphology, particle sizes, and functional group contents of the microspheres
were characterized by attenuated total reflection-Fourier transform infrared spectroscopy (ATR-FTIR), scanning electron, and optical
microscopy measurements. The obtained data demonstrated that the addition of CNF to the microsphere increased the encapsulation
efficiency of the IBR while allowing the controlled and gradual release of the drug. In terms of the encapsulation efficiency and drug
release rate, IBR@CS/TPP/CNF microspheres, achieving drug encapsulation efficiency of 83.09%, have the most suitable formulation
according to the comparative studies. Furthermore, according to Korsmeyer-Peppas kinetic model, IBR release mechanism was
anomalous diffusion (swelling-controlled behavior and diffusion.) because the IBR release profile was completed in 78 h under
optimized conditions. Therefore, the development of CNF based chitosan microsphere is a promising approach to assure appropriate
dosage, safety, and improving drug efficacy.
Key words: Chitosan, carbon nanofiber, composite, Ibrutinib, controlled drug delivery

1. Introduction
Controlled drug delivery is a multidisciplinary field that aims to achieve the desired clinical response in biological
organisms in the most effective way. Reducing excess chemical exposure protects the patient from side effects arising from
overdose and prevents early elimination of the drug by directing it to the targeted area. Drug delivery systems can have
a broad spectrum depending on the treatment of interest and successfully take place in the literature as an influencing
method for intensive drug treatments such as chemotherapy [1].
Ibrutinib (IBR), a small molecule chemotherapeutic that is used as irreversible inhibitor of Bruton’s tyrosine kinase
(BTK), and acts as a promising drug on several B-cell malignancies [2,3]. IBR is an approved drug for the treatment of
mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CCL) in the past 10 years [4]. IBR is mainly absorbed
very rapidly by the small intestine, mainly. Because IBR has poor solubility in water, its extremely low oral bioavailability
causes high dosage applications. As with most oral drugs, taking IBR in higher doses causes drug toxicity and undesired
side effects [5,6]. To overcome these problems, microspheres have received much attention to design efficient carrier
materials for controlled or sustained drug release. Microspheres are prepared using carbon-based materials such as carbon
nanofibers, carbon nanotubes, and graphene oxide for enhancing drug-loading capacity mechanical strength and release
drugs at desired times [7–9].
Carbon nanofiber (CNF), having special cylindrical or conical one-dimensional (1D) nanostructures, provide good
dispersibility and operability [10]. CNF is a potential candidate to increase the drug encapsulation efficiency, provide
mechanical strength, and sustained controlled release of the drug [11]. Moreover, the ability to make strong electrostatic
interactions with many adsorbates, low toxicity, high surface area, and flexibility allow CNF to combine various alternative
biomaterials, including chitosan.
Chitosan (CS) is a natural cationic polysaccharide which is obtained by deacetylation of chitin [12]. This natural polymer
has numerous important features such as excellent biocompatibility, biodegradability, ease-to-functionalize, and polycationic
character. These advantages provide several pharmaceutical applications to develop effective drug delivery systems
* Correspondence: cananarmutcu@hacettepe.edu.tr
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[13,14]. Chitosan microspheres can be prepared by many different approaches such as emulsification-solvent evaporation,
coacervation, spray drying, and ionotropic gelation [4,15–17]. However, chitosan microsphere prepared by chemical
crosslinker agent (usually glutaraldehyde), may occur their toxic reaction and undesirable effects. To solve this problem,
tripolyphosphate (TPP) is widely used as a nontoxic polyanion that can interact with chitosan via electrostatic forces [14,16].
IBR controlled release studies with different materials are available in the literature [4,18]. For example, Zhao et al.
prepared IBR-loaded nanoparticles based on chitosan and sulfobutylether- b-cyclodextrin (b-CD) and CS for IBR delivery.
The results showed that nanoparticles have displayed high the encapsulation efficiency (76.9%) with increasing SBE-b-CD
concentration [4]. Prasad et al. used Capryol 90 (oil), Cremophor RH40 (surfactant), and Transcutol P (cosurfactant) to
synthesize self-nanoemulsifying drug delivery system (SNEDDS) in the delivery of Ibrutinib by oral route. The release
studies were carried out pH 6.8 and the IBR release was achieved 83.78% in 15 min [18]. Herein, I used chitosan as the
main material of the microspheres, and TPP as the crosslinker. Chitosan-TPP microspheres have a biodegradable natural
structure while providing protection from undesirable toxic effects. Moreover, the addition of CNF to the structure during
the synthesis of microspheres increased the efficiency of drug encapsulation and provide the sustained controlled release
of the drug. As far as I know, the prepared materials, which displayed highly drug encapsulation efficiency of IBR, has not
been reported previously.
In this study, a new carbon nanofiber incorporated chitosan-based composite drug carrier was developed as an
alternative system while using TPP as a crosslinker. CS/TPP/CNF composite microspheres were synthesized by ionotropic
gelation method whereas the effecting parameters such as chitosan concentration, pH of TPP solutions, TPP concentration,
IBR concentration, CNF concentration and crosslinking time were comparatively investigated. The releasing profiles of
IBR from various CS/TPP/CNF composite microspheres were investigated to assure the safety and appropriate dosage of
the drug. In addition, this study offers and proves that CNF incorporated composite microspheres have a high potential
for releasing IBR in a sustained, controlled manner.
2. Materials and methods
2.1. Chemicals
Ibrutinib active ingredient was provided by TOBIO pharmaceuticals. Chitosan (medium molecular weight, and degree
of deacetylation ≥85%) and sodium tripolyphosphate (NaTPP, technical grade 85%) were supplied from Sigma-Aldrich.
Graphitized carbon nanofibers (200–600 nm outside diameter, 5–50 mm length) were supplied by Grafen Chemical
Industries Co. Sulphuric acid (H2SO4), nitric acid (HNO3), methanol (MeOH), and acetic acid (HAc) were of analytical
grade and obtained from Merck.
2.2. Preparation of composite microspheres
Chitosan/Tripolyphosphate/Carbon nanofiber (CS/TPP/CNF) microspheres containing Ibrutinib were prepared by an
ionotropic gelation procedure (Figure 1) [19]. For carbon nanofiber oxidation: the specific amounts of CNF powder were
dispersed in 8.0 mL, 4.0 M aqueous mixture of H2SO4/HNO3 (3/1, v/v) and treated at 70 °C for 180 min [20]. The treated
CNF powder was placed in a beaker and washed with deionized (DI) water until the pH value of the washing-out solution
was equal to 7.0. Washing removes O-bonded oxides to the carbon nanofiber, so directly N- and S- bonded oxides are
retained [21]. Then, the sample was dried at 70 °C for 48 h.
Herein, carbon nanofibers (CNFs) were treated with IBR in order to achieve proper drug loading to composite
microspheres. In this respect, a desired amount of IBR was added into 1.0 mL MeOH-deionized water solution and
subsequently magnetically stirred at 100 rpm at 25 °C for 2 h. Afterward, the CNF (0.05%, 0.1%, 0.2% w/v) was added
into the solution and stirred for 4 h to obtain homogeneous complex dispersion. Ibrutinib and Ibrutinib-CNF complexes
were dispersed in chitosan solutions in (2% v/v acetic acid) until homogenized dispersion was obtained. The composite
microspheres were formed by dropping via peristaltic pump (1.0 mL/min, flow rate) into TPP solution. The gelled
composite microspheres were collected and washed several times by DI water. Finally, IBR@CS/TPP/CNF microspheres
were isolated by filtration and lyophilized at –50 oC against 1.0 mmbar pressure for 48 h.
In this study, the effect of chitosan concentration (1.5%, 2%, 2.5% w/v), pH of TPP solutions (pH 5.0, pH 7.0, and
pH 8.8), TPP concentration (1%, 2%, 3% w/v), IBR concentration (10%, 20% and 25% w/w), CNF concentration (0.05%,
0.1%, 0.2% w/v), and crosslinking time (30, 60, and 120 min) were investigated for optimization of IBR@ CS/TPP/CNF
microsphere properties (Table 1).
2.3. Structural analyses of microspheres
The surface morphology of the composite microspheres was studied by scanning electron microscopy (SEM) (GAIA3,
Tescan, Brno, Czech Republic). The lyophilized microspheres were coated with a gold layer for enhancing conductivity.
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Figure 1. Schematic of the formation of IBR@CS/TPP/CNF microsphere.

Table 1. Formulations of the IBR@CS/TPP/CNF microspheres.

Code

Ibrutinib
(%w/w)

CNFs
(%w/v)

TPP
(%w/v)

pH of the external
phase

Chitosan
(%w/v)

Crosslinking time
(min)

C1

10

0.05

1

5.0

2

30

C2

10

0.05

1

7.0

2

30

C3

10

0.05

1

8.8

2

30

C4

10

0.05

2

5.0

2

30

C5

10

0.1

2

5.0

2

30

C6

10

0.2

2

5.0

2

30

C7

20

0.1

2

5.0

2

30

C8

25

0.1

2

5.0

2

30

C9

10

0.1

1

5.0

2

30

C10

10

0.1

3

5.0

2

30

C11

10

0.1

2

5.0

2

60

C12

10

0.1

2

5.0

2

120

C13

10

0.1

2

5.0

1.5

30

C14

10

0.1

2

5.0

2.5

30

C15

10

-

2

5.0

2

30

Attenuated total reflection-Fourier transform infrared (ATR-FTIR) spectrophotometer (Diffuse Reflectance, Thermo
model-NICOLET-IS 10 FTIR) was conducted to characterize the functional groups of microspheres. The ATR-FTIR
spectra of the composite microspheres were recorded from 4000 to 500 cm–1. Particle sizes were measured using an optical
microscope fitted with a micrometer by which the size of the microspheres could be determined. In order to calculate the
average size properly, fifty composite microspheres of all formulations were used in these measurements [19].
2.4. Determination of IBR encapsulation efficiency
IBR encapsulation efficiency was measured by dividing the trapped IBR amount in the microspheres by the total amount
of IBR added into the chitosan solution. The residual IBR in the TPP gelling and washing solutions was also collected
and measured by UV/Vis spectrophotometer (Shimadzu, UV-1280, Tokyo, Japan) at 260 nm. The drug encapsulation
efficiency of microspheres was calculated by using the following equation:
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(1)
All samples were repeated thrice while the average values were reported.
2.5. IBR release studies
The IBR releasing profiles of the composite microspheres were investigated in physiologic pH value. Briefly, 30 mg of the
composite microspheres were placed in 4.0 mL of buffer solutions (pH 6.8) at 37 ± 0.5°C and were placed on the shaking
incubator at 100 rpm (JSSB-30T, JSR, Gongju, Korea). IBR is a weakly basic drug whose solubility depends on pH. It is
soluble in acidic pH conditions, but weakly soluble in neutral pH conditions [22]. Furthermore, IBR is mainly absorbed
in the small intestine, thus the medium was adjusted to the simulated intestinal fluid (SIF, pH 6.8) to prevent the collapse
of Ibrutinib drug and to realize drug release effectively [4, 23]. In the predetermined time intervals, 0.4 mL of the buffer
solution was sampled and replaced with 0.4 mL of the fresh buffer solution to keep the volume of the release medium
constant. As a result, the amount of the released IBR was determined at 260 nm spectrophotometrically. All IBR release
studies were performed in triplicate to calculate the standard deviation.
2.6. IBR release kinetics
To understand the release mechanism of IBR from the composite microspheres, the release data were analyzed using three
standard kinetic models; zero-order (Eq. 2), first-order (Eq. 3), and Korsmeyer-Peppas (Eq. 4) models.
Zero-order model:
(2)
First-order model:
(3)
Korsmeyer-Peppas model:
(4)
The zero-order kinetic model is associated with a constant drug release rate, which is independent of the drug
concentration. The first-order kinetic model identified with the rate of release which is linearly dependent on its drug
concentration. Korsmeyer-Peppas model explains drug release from swellable polymeric systems, and drug release should
be one-dimensional. For the general equation to be used, the Mt/M∞ ratio must be less than 0.6 [24]. The determination
coefficient (R2) in each kinetic model was calculated after fitting the pure data to each equation.
For the Korsmeyer-Peppas model; Mt means the amount of drug release at time t, M∞ describes the amount of drug
release at an infinite time, k is the kinetic constant. The diffusional release exponent is n which is related to the mechanism
of drug release. In the case of Fickian release (diffusional controlled-release), n should be close to 0.43, and when exactly
equal to 0.43 [25]. The case II release occurs transport or swelling controlled, and n is 0.85. In the non-Fickian release, the
exponent of n is approximately 0.43 to 0.85, and the system is both diffusion and swelling controlled [26].
3. Results and discussion
3.1. Structural analysis
Figure 2 shows the SEM images of the CNF sample, C5, and C15 microspheres. CNFs were formed a tight network that
looks like tangled and hollow ropes (Figure 2a) [27]. Figure 2b indicates that the surface of C5 composite microspheres was
quite smooth. However, the presence of CNF in the C5 composite microspheres changed the surface of microspheres to
make the surface more wrinkled and rough. Moreover, adding CNF into chitosan resulted in folded chitosan microsphere
surface [16]. To explain briefly, C5 composite microspheres were composed with the electrostatic interactions between
negatively charged oxide CNFs and positively charged chitosan. It reduced the van der Waals forces among CNF clusters
by wrapping the CNFs in the polymer structure, so a crinkly rough structure was formed on the surface [28]. Besides, from
the SEM image of chitosan microsphere, it was clear that CNFs were trapped inside internal texture of microsphere which
prevents the diffusing of the drug easily (Figure 2b), while IBR did not encounter hardship in release from the chitosan
microspheres without CNF (Figure 2c).
Functional groups of IBR, bare chitosan, and C5-coded composite microsphere were determined using ATR-FTIR
spectrometer (Figure 3). The main characteristic bands of IBR (Figure 3a) were observed for -N-H stretching peaks
at 3444 cm−1 and, for C-H stretching peaks at 2972 cm−1. Moreover, the bands at the 1565, 1474, and 1233 cm−1 were
attributed C=C–C stretching, C=N stretching, and C-N stretching of an aromatic ring found in IBR structures. The broad
peak at 3353 cm−1 corresponds to O-H groups vibrations in the chitosan spectrum (Figure 3b). The bands at 2872 cm−1
corresponded to stretching vibrations connected with the C−H bond. The peaks at 1647 and 1377 cm−1 belong to N-H and
C-N stretching vibrations, respectively. The bands at 1027 cm−1 is due to the vibration of –C–O–C– groups. According to
the spectra for C5-coded composite microsphere, the peak at 1630 cm-1 is ascribed to the stretching band of C=O in the
structure of carbon nanofibers (Figure 3c). The characteristic peaks of IBR disappeared in the C5 microsphere due to the
overlap of bands in this region comprising the deformation of -OH, -NH, and -CHx groups. This situation can be explained
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due to the small IBR ratio [4] while the bands at 859 cm−1 indicate the present of the aromatic group (CH=CH) of IBR on
the surface of CNF.
The particle size distribution of the microspheres varied between 0.58 and 1.16 mm (Table 2). The mean particle size
increased with increasing the amount of chitosan, which also increased the viscosity of the polymer concentration [19]. In
addition, the increase in TPP concentration [19] and crosslinking time [29] caused a further increased in the particle size
of the microspheres, as expected.

Figure 2. SEM images of CNF (a); C5-coded composite microsphere (b) and
C15 microsphere (c).

Table 2. Particle size analysis of the formulations.
Formulation code

Arithmetic mean particle size (mm)

Formulation code

Arithmetic mean particle size (mm)

C1

1.04 ± 0.01

C9

0.88 ± 0.04

C2

1.14 ± 0.09

C10

1.06 ± 0.05

C3

1.10 ± 0.11

C11

0.94 ± 0.02

C4

1.02 ± 0.03

C12

0.96 ± 0.12

C5

0.90 ± 0.01

C13

0.58 ± 0.04

C6

1.08 ± 0.06

C14

1.16 ± 0.03

C7

0.94 ± 0.02

C15

0.94 ± 0.01

C8

0.84 ± 0.03

-

-
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3.2. Drug entrapment efficiency
Encapsulation efficiencies of IBR ranged between 17.80% and 87.55% in the formulations. The encapsulation efficiencies
of C1, C2, and C3-coded composite microspheres were calculated as 49.89%, 31.55%, and 17.80%, respectively. When the
pH of TPP solutions increased, the solubility of IBR increased in the external phase so the encapsulation efficiency was
considerably reduced [29–31]. Considering the encapsulation efficiency, the pH of the TPP solution was kept constant at
5.0 in all formulations to retain the drug within the composite microspheres, and encapsulation efficiency significantly
increased with the CNF content in synthesized composite microspheres. Electrostatic interactions between oxygenated
functional groups of CNFs and IBR, together with hydrogen bonds, are the main reason for the increase in encapsulation
efficiency. The studies suggested that formulations with higher ratios of chitosan, CNFs, and TPP improved the drug
entrapment efficiency and decreased with increasing crosslinking time. (Table 3).
3.3. IBR release studies
As seen in Figure 4, C15 microspheres showed the maximum primary burst release of IBR in the only early hours. The
release profile of IBR from C15 realized fast and higher release rates about 7-fold of C6-coded composite microsphere
within 12 h. An important reduction occurs in the primary burst release of IBR from microspheres by incrementing

Figure 3. ATR-FTIR spectra of IBR (a), chitosan (b), C15
microsphere (c).
Table 3. Encapsulation efficiency of the formulations.

Formulation code

Encapsulation
efficiency (EE, %)

Formulation code

Encapsulation
efficiency (EE, %)

C1

49.89

C9

72.46

C2

31.55

C10

87.22

C3

17.80

C11

81.23

C4

81.60

C12

77.01

C5

83.09

C13

79.85

C6

84.31

C14

87.55

C7

83.58

C15

39.87

C8

86.10

-

-
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the CNF amount. This may be explained by the presence of CNF into composite resulted in a more extended pathway
for migrating IBR from inside of composite into the release medium compared with the C15 microspheres; therefore, it
prolongs the release time. Also, the attractive electrostatic interactions occur between the IBR and the CNFs oxidized as
well as hydrogen bonding.
The release rate of IBR was studied with different concentrations (10%–25%) of the drug in the composite microspheres.
As seen in Figure 5, there was no significant difference in drug release when the IBR concentration in composite structure
increased from 10% to 20%. However, the increasing concentration to 25% caused a significant IBR release rate because
of the increasing abundance of IBR amount in the composite network causing the higher diffusion rate of the drug [32].
The effect of chitosan concentration on IBR releasing profile was performed in the concentration ranges of 1.5–2.5%
w/v (Figure 6). An obvious decrease is seen in the release rate of IBR with increasing the concentration of chitosan in the
composite microspheres. Because of the increase in the polymer concentration, chitosan results in a thicker polymeric
shell while increasing the crosslinking density, which causes the formation of a compact structure and, in the end, reduces
drug release [29].
The release rate of IBR decreased where the crosslinking agent TPP concentrations were increased from 1% w/v, 2%
w/v, and 3% w/v in C9, C5, and C10-coded composite microspheres, respectively (Figure 7). Crosslinking was occurred
through electrostatic forces between negative-charged phosphate groups of TPP and positive-charged amine groups
in chitosan [33]. Thus, the crosslinking in the structure of the chitosan microspheres increases, and a rigid structure is
formed that is responsible for more slow drug release. In other words, a less permeable denser matrix structure is formed
for drug release [34].
The effect of crosslinking time on the IBR release was carried out at 30, 60, and 120 min, and IBR release data was
presented in Figure 8. The long crosslinking time leads to a decrease in drug release because more crosslinked and rigid
TPP/chitosan matrices were obtained [35]. As observed in Figure 8, the composite microsphere prepared in TPP solution
(%2, w/v) for 30 and 60 min showed faster release behavior than those of composite prepared for longer crosslinking time
(120 min). When the crosslinking time increased from 30 min to 60 min, no significant difference was observed in terms
of release rate while drug release for C12 was decreased with increasing the crosslinking time to 120 min. This is attributed
to the fact that, a more crosslinked structure was formed with increasing the crosslinking time from 30 to 120 min, as
was also reported in the literature [36]. Considering the stability of the structure and the encapsulation efficiency, it was
decided that the 30 min crosslinking time was sufficient and admitted for further studies.
3.4. IBR release kinetics
The release data of IBR from composite microspheres was evaluated via fitting to three kinetic models, including zero
order, first order, and Korsmeyer-Peppas. The IBR release kinetics parameters as a summary of release exponent (n) values
and correlation coefficient were presented in Table 4. As seen in Table 4, the Korsmeyer-Peppas kinetic model was the
best fitted model for the entire composite microsphere (R2 > 0.944). The exponent values for the release of IBR from the
microsphere within 0.43–0.85 indicate a non-Fickian release performance. For both diffusion and swelling-controlled via
swelling, the microspheres were the effective factors in controlling IBR release [16,37,38].

Figure 4. Effect of the CNF content on the IBR release from
microspheres: C15 (–), C4 (0.05%), C5(0.1%), and C6 (0.2%).
Each experiment was done three times in triplicates.

1638

Figure 5. Effect of the drug concentration on the IBR release
from composite microsphere: C8 (25%), C5 (10%), and C7
(20%). Each experiment was done three times in triplicates.
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Figure 6. Effect of the chitosan concentrations on the IBR release
from composite microspheres: C13 (1.5%), C5 (2%), and C14
(2.5%). Each experiment was done three times in triplicates.

Figure 7. Effect of the TPP concentrations on the IBR release
from composite microspheres: C9 (1%), C5 (2%), and C10(3%).
Each experiment was done three times in triplicates.

Figure 8. Effect of the crosslinking time on the IBR release from
composite microspheres: C11 (60 min), C5 (30 min), and C12
(120 min). Each experiment was done three times in triplicates.
Table 4. Release kinetics data for chitosan microspheres.

Formulation
C4
C5
C6
C7
C8
C9
C10
C11
C12
C13
C14
C15

Zero-order

First-order

Korsmeyer-Peppas

R

R

R2

n

0.934
0.936
0.961
0.929
0.946
0.953
0.977
0.949
0.917
0.941
0.958
0.887

0.677
0.663
0.707
0.626
0.682
0.668
0.745
0.684
0.640
0.636
0.744
0.632

0.983
0.990
0.985
0.944
0.967
0.962
0.983
0.961
0.975
0.968
0.982
0.957

0.842
0.812
0.78
0.758
0.703
0.741
0.655
0.761
0.827
0.845
0.666
0.762

2

2

1639

ARMUTCU / Turk J Chem
4. Conclusion
In this study, a CNF-incorporated chitosan-based drug delivery system was designed through dispersing oxidized CNF in
the chitosan after crosslinking with TPP. The developed microspheres had a particle size between 0.58 and 1.16 mm. The
obtained data demonstrated that the addition of CNF to the microsphere structure increased the encapsulation efficiency
of the IBR from 39.87% to 87.75% and resulted in a more controlled and gradual release of the drug. C5-coded composite
microspheres were determined to be the most suited formulation in terms of encapsulation efficiency and medication
release rate (EE, 83.09%). The results indicated that the release data were fitted well to Korsmeyer-Peppas kinetic model
(R2 > 0.944) and the release mechanism was anomalous diffusion (swelling-controlled behavior and diffusion), in which
IBR could release at pH 6.8 within 78 h in a more controlled manner. Finally, the development of CNF based chitosan
microsphere is a promising material to assure appropriate dosage use, safety, and improving drug efficiency.
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